Monash University study links low-dose aspirin to reduced dementia risk for specific genetic groups
Researchers at Monash University published findings on October 25, 2026, indicating that low-dose aspirin lowers dementia risk by 70 percent in older adults with a particular genetic profile.
Genetic factors determine drug response
Scientists analyzed data from over 13,500 participants in the ASPREE Trial to examine individual differences. They discovered that people carrying certain genes experienced a significantly lower relative risk of developing dementia while taking the medication. Previous research had shown no overall protective effect for aspirin across the entire population.
Potential for targeted prevention
The results suggest that genetic testing might eventually help identify which individuals could benefit from this preventive treatment. This approach explains why some patients respond to the drug while others do not show any change in risk. The study was released in the journal Alzheimer's & Dementia.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.